ArticleBMC infectious diseases2026
Comparative effectiveness of tenofovir versus entecavir combined with peginterferon Alfa-2b for functional cure in HBeAg-negative chronic hepatitis B: a propensity score-matched analysis.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundData directly comparing the efficacy of tenofovir disoproxil fumarate (TDF) versus entecavir (ETV) in combination with peginterferon alfa (PEG-IFNα) for functional cure in chronic hepatitis B (CHB) remain scarce. This study aimed to compare the functional cure rates between these two combination regimens in HBeAg-negative CHB patients.
methodsA total of 442 HBeAg-negative CHB patients (ETV group 238 and TDF group 204) with HBsAg levels below 1500 IU/mL were included. All patients received PEG-IFNα-2b once a week based on the chronic administration of ETV or TDF. Study endpoint was functional cure of the patients. Propensity Score Matching (PSM) and inverse probability of treatment weighting (IPTW) methods were used in our study.
resultsHBsAg levels declined significantly throughout the treatment in both groups. In the original cohort, the TDF group exhibited a higher functional cure rate at week 48 compared to the ETV group (35.78% vs. 25.63%, p = 0.021). However, this difference was abolished after PSM (p = 0.445) and IPTW adjustment (p = 0.336), demonstrating no significant disparity between the regimens. Multivariable analysis identified younger age and lower baseline HBsAg levels as independent favorable factors for functional cure, while the choice of NA (TDF vs. ETV) was not a significant predictor.
conclusionsThis study has demonstrated that in HBeAg-negative CHB patients with low HBsAg levels, the combination of PEG-IFNα-2b with either TDF or ETV leads to comparable rates of functional cure. Younger age and lower baseline HBsAg level are favorable factors for treatment effect, but not TDF or ETV.
trial registrationChiCTR number: ChiCTR1800020369 (2018-12-25).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.